Esophageal Cancer Systemic Therapy

Scope and treatment selection

Systemic therapy should be selected according to resectability, anatomic extent, treatment intent, histology, prior therapy, nutritional status, and the feasibility of surgery or radiotherapy. The available evidence in these references is heterogeneous: randomized trials and meta-analyses inform perioperative and advanced-disease treatment, whereas several studies are retrospective, exploratory, or protocol reports and should not be interpreted as definitive comparative evidence.^{[2]A1a[3]A1a[7]B2b[9]A1b[10]B2b[17]A1b[20]B3b}

Resectable, locally advanced disease

For patients proceeding to curative-intent esophagectomy, neoadjuvant treatment is the principal systemic-therapy setting represented by the cited evidence. A meta-analysis of three randomized trials involving 375 patients found that neoadjuvant chemoradiotherapy (nCRT) produced higher R0-resection and pathological complete-response rates than neoadjuvant chemotherapy (nCT), but did not significantly improve 3- or 5-year progression-free or overall survival.^[3]A1a Thus, nCRT may be favored when maximizing tumor regression, margin-negative resection, or pathological response is the immediate objective, while the survival advantage over nCT remains unproven in this pooled analysis.^[3]A1a

Treatment tolerance and nutritional trajectory should be assessed during neoadjuvant therapy. In an exploratory analysis of the OGSG1003 randomized phase-II dataset in locally advanced esophageal squamous cell carcinoma, weight loss during neoadjuvant chemotherapy was evaluated in relation to postoperative infectious complications and prognosis; tumor stenosis and treatment adverse events were recognized contributors to weight loss.^[7]B2b This supports active nutritional and functional monitoring rather than treating systemic therapy as an isolated anticancer intervention.^[7]B2b

After curative R0 resection, adjuvant systemic therapy remains regimen- and population-dependent. In a randomized phase-II study of 62 patients with node-positive esophageal squamous cell carcinoma, adjuvant leucovorin/5-fluorouracil (LV5FU2) was compared with LV5FU2 plus oxaliplatin (FOLFOX), with disease-free survival as the primary endpoint; the study specifically addressed the unresolved optimal perioperative approach.^[8]B2b Retrospective evidence in 125 patients with stage IIB–IVA disease evaluated postoperative concurrent chemoradiotherapy: 97.6% received more than 50 Gy, but only 41.6% received more than five weeks of chemotherapy, illustrating the importance of completion and tolerability when postoperative chemoradiation is used.^[16]A1b

Locally advanced unresectable disease

For locally advanced unresectable thoracic squamous-cell carcinoma, definitive chemoradiotherapy with cisplatin plus 5-fluorouracil was identified as the contemporary standard in the JCOG1510/TRIANgLE phase-III protocol.^[9]A1b The trial was designed to test whether induction docetaxel, cisplatin, and 5-fluorouracil followed by conversion surgery or definitive chemoradiotherapy improves overall survival compared with definitive chemoradiotherapy alone; because the cited report describes the trial design, it does not establish superiority of the induction strategy.^[9]A1b

Radiotherapy-related toxicity may require supportive management. In a randomized trial of 60 patients with esophageal or gastric-cardia cancer receiving chemoradiotherapy, oral famotidine 40 mg daily, administered four hours before each radiation session, was compared with placebo to assess hematologic complications.^[6]A1b The intervention should therefore be regarded as an investigated supportive-care strategy, not as established anticancer systemic therapy.^[6]A1b

Unresectable advanced or metastatic disease

For previously untreated advanced esophageal cancer, pembrolizumab plus chemotherapy is the key first-line immunochemotherapy setting represented here. The Japanese subgroup of KEYNOTE-590 received pembrolizumab 200 mg every three weeks for up to 35 cycles or placebo, combined with cisplatin 80 mg/m² and 5-fluorouracil 800 mg/m²/day; the five-year analysis used a July 10, 2023 data cutoff and followed participants with overall and progression-free survival, response, and safety endpoints.^[4]A1b A Japanese cost-effectiveness model likewise evaluated pembrolizumab plus chemotherapy versus chemotherapy alone from the healthcare-payer perspective, including a programmed-death-ligand 1 combined positive score subgroup of CPS ≥10.^[5]A1b

After progression, second-line nivolumab monotherapy has real-world activity in unresectable or metastatic disease. In a multicenter cohort of 184 patients, the response rate among 128 patients with measurable lesions was 23%, disease control for the full cohort was 45%, and grade ≥3 adverse events occurred in 14%, with no treatment-related deaths reported.^[10]B2b These outcomes support nivolumab as a reasonable post-first-line option when clinically appropriate, while recognizing the nonrandomized design.^[10]B2b

Other investigational or nonstandard systemic approaches should not displace evidence-supported therapy. In a phase-II study of pretreated advanced squamous carcinoma, the PI3K inhibitor BKM120 yielded stable disease in 20 of 42 patients and confirmed partial response in 2 patients.^[13]B2b A randomized study of Xiaoaiping plus S-1/cisplatin enrolled 124 patients with advanced disease and compared the combination with S-1/cisplatin alone, but the cited information does not provide sufficient outcome detail to establish routine use.^[17]A1b

Oligometastatic and recurrent disease

Oligometastatic esophagogastric cancer requires multidisciplinary assessment rather than automatic systemic therapy alone. A systematic review and meta-analysis evaluated definitions based on the maximum number of involved organs and lesions per organ and compared metastasectomy or stereotactic radiotherapy with systemic therapy alone; the review’s purpose was to determine whether local oligometastasis-directed treatment may improve overall survival, but definitions were heterogeneous across studies.^[2]A1a

For locally recurrent disease after definitive chemoradiotherapy, salvage photodynamic therapy with talaporfin sodium has been evaluated, including lesions exceeding the original clinical-trial boundaries of luminal circumference ≤1/2, longitudinal length ≤3 cm, and absence of cervical-esophageal invasion.^[19]C4 Because the expanded-indication study was retrospective and included 34 consecutive patients, salvage PDT should be individualized and delivered in experienced centers.^[19]C4

Monitoring, supportive care, and safety

Early tumor shrinkage of 20% at the first assessment was examined as a prognostic marker in a real-world observational cohort of 128 patients with unresectable or recurrent squamous carcinoma treated with immune-checkpoint-inhibitor combinations; this evidence is hypothesis-generating rather than treatment-selecting.^[61] Immune-related adverse events and long-term survival were also assessed retrospectively in patients receiving immune-checkpoint-inhibitor combinations, but the single-center design limits causal interpretation.^[18]C4 ctDNA-guided response assessment is being studied in previously treated gastroesophageal adenocarcinoma, including baseline levels and early changes during trifluridine-tipiracil with or without bevacizumab; this does not yet establish ctDNA-guided treatment switching for esophageal cancer.^[12]B2b

Perioperative analgesic choices matter: a cohort of 557 patients undergoing gastroesophageal-junction cancer surgery evaluated ketorolac and other NSAIDs in relation to anastomotic leakage.^[11]B2b Endoscopic submucosal dissection remains a local-treatment context for selected superficial squamous lesions; a prospective study of 65 patients evaluated dexmedetomidine plus midazolam sedation without intubation.^[14]B2b Finally, GLP-1 receptor agonists should not be withheld solely because of presumed esophageal-cancer risk: a meta-analysis of 6 studies and 13,391 participants found a pooled relative risk of 0.46 (95% CI 0.22–0.97) versus control agents in adults with type 2 diabetes or obesity.^[1]A1a

Role and treatment settings

Concurrent chemoradiotherapy (CRT) combines radiation with radiosensitizing systemic therapy and is used in both definitive and neoadjuvant strategies for esophageal cancer. For locally advanced unresectable thoracic squamous-cell carcinoma, definitive CRT (dCRT) with cisplatin plus 5-fluorouracil (5-FU) is described as the current standard treatment. The phase III JCOG1510/TRIANgLE study was designed to test whether induction docetaxel, cisplatin, and 5-FU (DCF), followed by conversion surgery or dCRT, improves overall survival compared with definitive cisplatin/5-FU CRT alone; the planned enrollment was 230 patients across 47 Japanese institutions. ^[9]A1b A subsequent correlation analysis specifically addresses event-free survival as a potential surrogate for overall survival in randomized trials of dCRT for unresectable locally advanced disease, but the provided abstract does not report a treatment effect or establish a replacement for overall survival. ^[21]A1a

Neoadjuvant CRT before surgery

For potentially resectable disease, neoadjuvant CRT followed by esophagectomy increases tumor and surgical response metrics compared with neoadjuvant chemotherapy alone. A meta-analysis of 3 randomized trials including 375 patients found that CRT significantly increased the R0 resection rate and pathologic complete response rate. However, it did not demonstrate a significant improvement in 3- or 5-year progression-free survival or 3- or 5-year overall survival versus chemotherapy alone. ^[3]A1a These findings support CRT as an effective method for improving local pathologic response and the probability of complete resection, while indicating that improved short- or intermediate-term survival cannot be assumed solely from higher pCR or R0 rates. ^[3]A1a

A Japanese prospective study evaluated selective CRT after endoscopic resection in patients with T1b (SM1–2) N0M0 thoracic esophageal squamous-cell carcinoma. Patients with pT1b disease and a negative margin, or pT1a disease with lymphovascular invasion, received prophylactic CRT directed to locoregional lymph nodes with 41.4 Gy; patients with low-risk pT1a disease with negative margins and no lymphovascular invasion received no additional treatment. ^[24]B2b This approach illustrates risk-adapted use of CRT after endoscopic treatment rather than routine esophagectomy for every superficial lesion. ^[24]B2b

Definitive and post-endoscopic CRT

For cT1bN0M0 squamous-cell carcinoma, dCRT is described as a curative option, although local residual or recurrent disease may occur. A retrospective study of 40 patients evaluated endoscopic features associated with non-radical cure after dCRT; the abstract reports 10 patients with residual or recurrent disease and 30 without, but does not provide sufficient detail to define a validated selection algorithm. ^[34]C4

After noncurative endoscopic submucosal dissection (ESD) for superficial squamous-cell carcinoma, CRT is an alternative to esophagectomy in selected patients. A retrospective comparison included 34 patients treated with CRT and 26 treated surgically; the abstract indicates that long-term oncologic outcomes were compared but does not provide the numerical survival results. ^[62] Another retrospective series used definitive-dose RT after ESD for superficial cancers at high risk of nodal spread, including muscularis-mucosa involvement with lymphovascular invasion or upper/mid-thoracic disease; RT doses ranged from 50 to 61.2 Gy, with or without chemotherapy. ^[31]B3b These studies are nonrandomized and should not be interpreted as establishing equivalence between CRT and surgery. ^[31]B3b[62]

Recurrent disease and treatment intensification

Salvage CRT is used for selected locoregional recurrence after esophagectomy. In a retrospective cohort of 147 patients receiving salvage RT, RT alone was delivered as 60 Gy in 20 fractions, whereas concurrent CRT used 60–70 Gy in 30–35 fractions. The study reports clinical outcomes after salvage treatment but does not establish a randomized comparison between RT alone and CRT. ^[32]C4

Induction chemotherapy before definitive CRT remains investigational in the cited evidence. JCOG1510 was designed to evaluate induction DCF followed by conversion surgery or dCRT, rather than to confirm that induction therapy should routinely precede CRT. ^[9]A1b Similarly, pembrolizumab plus cisplatin/5-FU has been studied as first-line therapy for previously untreated advanced esophageal cancer, but this regimen was administered as systemic therapy and the cited study does not evaluate concurrent RT. ^[4]A1b

Response assessment and supportive considerations

Imaging may help assess response during or after CRT, but it should not replace clinical and endoscopic evaluation. A meta-analysis evaluated MRI parameters for predicting early response to neoadjuvant therapy or concurrent CRT, while a prospective cohort of 38 squamous-cell carcinoma patients found that all patients had either complete response (52.6%) or partial response (47.4%) at completion of CRT; serial diffusion-weighted MRI and apparent diffusion coefficient changes were investigated as early response markers. ^{[22]B2a[28]C4} Meta-analyses also evaluated interim or post-treatment 18F-FDG PET for predicting pathologic response and survival after neoadjuvant CRT, although the cited abstracts do not provide a single universally applicable PET threshold. ^{[25]B2a[26]B2a}

Weight loss during preoperative chemotherapy—not specifically concurrent CRT—was investigated in the OGSG1003 exploratory analysis because stenosis and treatment toxicity can impair nutrition; its findings should not be directly extrapolated to CRT without confirming the treatment context. ^[7]B2b Likewise, FOLFOX has been explored as preoperative chemotherapy for cisplatin-ineligible patients, including those aged ≥75 years or with renal or cardiac dysfunction, but the cited study does not establish FOLFOX as a concurrent radiosensitizing regimen. ^[38]C4

Overview

Systemic chemotherapy selection depends on treatment intent, resectability, histology, comorbidity, and whether radiotherapy, surgery, or immune-checkpoint inhibition is incorporated. The evidence supplied includes perioperative, definitive chemoradiotherapy, unresectable/metastatic, and post-progression regimens, with several studies focused specifically on esophageal squamous-cell carcinoma (ESCC). ^{[3]A1a[9]A1b[15]B2b[38]C4[63]}

Neoadjuvant and perioperative chemotherapy

For locally advanced resectable disease, neoadjuvant chemotherapy (nCT) and neoadjuvant chemoradiotherapy (nCRT) are both evaluated approaches. A meta-analysis of 3 randomized trials including 375 patients found that adding radiotherapy to chemotherapy significantly increased R0 resection and pathological complete response rates compared with nCT alone; however, it did not significantly improve 3- or 5-year progression-free survival or overall survival. ^[3]A1a

In the Japanese OGSG1003 phase II trial, the neoadjuvant chemotherapy comparison was cisplatin plus fluorouracil (CF) with Adriamycin versus CF with docetaxel (DCF-related therapy) in patients with locally advanced ESCC. The exploratory analysis specifically examined treatment-associated weight loss and postoperative infectious complications, underscoring the importance of nutritional and toxicity monitoring during chemotherapy. ^[7]B2b Loss of skeletal muscle during neoadjuvant treatment was also associated with worse prognosis in a retrospective cohort of 115 patients undergoing neoadjuvant therapy and surgery. ^[40]B3b

For patients unable to receive cisplatin because of renal or cardiac dysfunction or advanced age, preoperative FOLFOX—oxaliplatin, leucovorin, and 5-fluorouracil—was evaluated retrospectively in resectable locally advanced ESCC. The regimen was administered every 2 weeks for 3 or 4 cycles and was selected because it has less renal toxicity and does not require the hydration associated with cisplatin-containing treatment. ^[38]C4

Adjuvant chemotherapy remains an area of uncertainty in node-positive ESCC. A randomized phase II study compared biweekly leucovorin/5-fluorouracil (LV5FU2) with FOLFOX for up to 8 cycles after curative R0 resection. Only 62 patients were randomized, so the study provides limited comparative evidence for selecting one regimen over the other. ^[8]B2b

Chemoradiotherapy regimens

The CROSS regimen consists of weekly carboplatin (area under the curve 2) plus paclitaxel 50 mg/m² with concurrent external-beam radiotherapy, followed by resection. In daily-practice data, treatment used 5 weekly courses and 23 fractions of 1.8 Gy; modified institutional protocols have also used radiation doses above 41.4 Gy with concurrent carboplatin/paclitaxel before esophagectomy. ^{[37]B3b[36]B2b}

For locoregional esophageal or gastroesophageal-junction cancer, retrospective comparative data evaluated carboplatin/paclitaxel versus cisplatin/fluorouracil in both trimodality therapy and definitive chemoradiotherapy. Carboplatin/paclitaxel-based nCRT followed by surgery was described as the standard approach at the reporting center, while cisplatin/fluorouracil remained an alternative for nCRT or definitive treatment. ^[63]

Definitive chemoradiotherapy with cisplatin plus 5-fluorouracil is the Japanese reference treatment for locally advanced unresectable thoracic ESCC. The JCOG1510 (TRIANgLE) phase III trial was designed to test induction docetaxel plus cisplatin and 5-fluorouracil (DCF), followed by conversion surgery or definitive chemoradiotherapy, against definitive cisplatin/5-fluorouracil chemoradiotherapy alone. ^[9]A1b

Capecitabine can substitute for infusional 5-fluorouracil in cisplatin-based definitive chemoradiotherapy. In a pilot study, patients received cisplatin 60 mg/m² on day 1 plus capecitabine 825 mg/m² twice daily on days 1–14 every 3 weeks, with radiotherapy to 60 Gy; two additional cycles of capecitabine/cisplatin were given after chemoradiotherapy. ^[42]C4

Unresectable or metastatic disease

Pembrolizumab plus chemotherapy is identified as recommended first-line therapy for unresectable advanced esophageal cancer in the Japanese cost-effectiveness analysis. ^[5]A1b In the Japanese subgroup of KEYNOTE-590, pembrolizumab 200 mg every 3 weeks for up to 35 cycles was combined with cisplatin 80 mg/m² and 5-fluorouracil 800 mg/m²/day and compared with placebo plus the same chemotherapy backbone. The study reported 5-year follow-up of previously untreated advanced esophageal cancer. ^[4]A1b

For metastatic, unresectable ESCC, irinotecan plus cisplatin was studied at irinotecan 65 mg/m² and cisplatin 30 mg/m² on days 1 and 8 of a 21-day cycle. In a phase II study of 27 patients, the objective response rate among 20 per-protocol patients was 30.0% with a 90% confidence interval of 13.2%–46.9%. ^[15]B2b

S-1 plus cisplatin was used as chemotherapy in a multicenter randomized study of advanced esophageal cancer; the experimental arm added Xiaoaiping. Both groups received treatment in 21-day cycles, with 62 patients per group. Because Xiaoaiping is an adjunctive intervention rather than a cytotoxic regimen, these results should not be interpreted as evidence that it replaces standard chemotherapy. ^[17]A1b

Real-world immune-checkpoint inhibitor combination therapy has also been reported for unresectable or metastatic esophageal cancer. In a retrospective cohort of 71 patients, the response rate among patients with measurable lesions was 58%, disease-control rate was 80%, and 5 patients (7.0%) underwent conversion surgery; grade ≥3 immune-related adverse events occurred in 13%, and one patient died from cholangitis. ^[39]C4

Later-line and investigational combinations

For refractory advanced gastroesophageal cancer, nivolumab was combined with irinotecan plus 5-fluorouracil (FOLFIRI) in a phase II study designed primarily to evaluate safety, treatment delays, dose reductions, response, overall survival, and progression-free survival. ^[41]B2b In gastroesophageal adenocarcinoma, commonly sequenced later-line options include ramucirumab plus paclitaxel, a taxane, irinotecan, or trifluridine/tipiracil; a retrospective sequencing study compared ramucirumab/paclitaxel followed by FOLFIRI or CAPEIRI with the reverse sequence. ^[64]C

Circulating tumor DNA-guided treatment monitoring remains investigational in previously treated metastatic gastroesophageal adenocarcinoma. A retrospective analysis assessed baseline ctDNA and early ctDNA changes during trifluridine/tipiracil with or without bevacizumab for prognosis, patient selection, and on-treatment response evaluation. ^[12]B2b

Practical safety considerations

Weight loss and skeletal-muscle depletion during neoadjuvant treatment are clinically relevant because both have been investigated in relation to postoperative complications and prognosis. Nutritional assessment, toxicity surveillance, and regimen adaptation are particularly important when treatment-related stenosis, adverse events, renal dysfunction, cardiac dysfunction, or older age limit chemotherapy tolerance. ^{[7]B2b[38]C4[40]B3b}

Scope and treatment setting

Immune checkpoint inhibition has become a central systemic-treatment strategy for advanced esophageal cancer, particularly when combined with first-line chemotherapy. The supplied evidence is strongest for esophageal squamous cell carcinoma (ESCC), although some studies include broader esophageal or gastroesophageal populations. ^{[44]A1a [4]A1b} Historical reviews describe immunotherapy as an evolving treatment pillar alongside surgery, chemotherapy, and radiotherapy, with early activity reported for pembrolizumab and nivolumab. ^{[46]D5 [48]D5}

For resectable disease, surgery remains the curative modality in appropriately fit patients. Trimodality therapy is generally emphasized for localized ESCC, whereas preoperative chemoradiotherapy or perioperative chemotherapy has been used for esophageal adenocarcinoma (EAC). ^[65]D Earlier evidence indicates that ESCC responds better to neoadjuvant chemoradiotherapy than EAC, while both neoadjuvant chemoradiotherapy and perioperative chemotherapy are effective approaches for EAC. ^[49]D5

First-line immune checkpoint inhibition

The phase 3 KEYNOTE-590 program evaluated pembrolizumab plus platinum–fluoropyrimidine chemotherapy in previously untreated advanced esophageal cancer. In the Japanese subgroup, the regimen consisted of pembrolizumab 200 mg every 3 weeks, for up to 35 cycles, with cisplatin 80 mg/m² and 5-fluorouracil 800 mg/m²/day; overall survival (OS) and progression-free survival (PFS) were assessed by investigator review using RECIST v1.1. ^[4]A1b Earlier follow-up showed numerically improved OS and PFS versus placebo plus chemotherapy in Japanese participants, and the 5-year follow-up used a data cutoff of July 10, 2023; the supplied abstract identifies 141 of 794 overall study participants as Japanese but does not provide the corresponding final numerical efficacy estimates. ^[4]A1b

The comparative first-line evidence base includes serplulimab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, sintilimab, toripalimab, and atezolizumab-containing regimens evaluated across ASTRUM-007, CheckMate 648, ESCORT-1st, GEMSTONE-304, JUPITER-06, KEYNOTE-590, ORIENT-15, and RATIONALE-306. ^[44]A1a A systematic review used individual-patient data from ASTRUM-007 and aggregate data from seven comparator trials, applying matching-adjusted indirect comparisons (MAICs) to align key baseline characteristics in treatment-naïve ESCC. ^[44]A1a Because these are indirect comparisons rather than head-to-head randomized trials, apparent differences among antibodies should be interpreted cautiously and should not be treated as proof of superiority without direct comparative evidence. ^[44]A1a

The clinical value of adding pembrolizumab is not determined solely by efficacy. A Japanese cost-effectiveness analysis modeled pembrolizumab plus chemotherapy versus chemotherapy alone from the Japanese healthcare-payer perspective using a partitioned-survival model, randomized-trial parameters, and a nationwide administrative database; it also prespecified a subgroup with PD-L1 combined positive score (CPS) ≥10. ^[5]A1b The supplied abstract describes evaluation of the incremental cost-effectiveness ratio and quality-adjusted life years but does not report the final numerical estimates. ^[5]A1b

Biomarker selection and safety considerations

PD-L1 expression is the principal predictive biomarker discussed in the supplied evidence, but its assessment is complicated by differences among assays, platforms, scoring systems, and individual agents. ^[47]D5 Earlier phase 3 evidence summarized in the literature indicates that second-line PD-1 inhibitor benefit was particularly evident in esophageal cancers with PD-L1 CPS ≥10, while the overall population benefit and regulatory indications vary by agent and treatment setting. ^[46]D5 Biomarker interpretation should therefore be linked to the specific drug, approved indication, assay, and line of therapy rather than extrapolated across all checkpoint inhibitors. ^[47]D5

Body composition may also influence outcomes during immune checkpoint inhibitor treatment. In a database of 111 patients with unresectable or recurrent esophageal cancer, investigators evaluated body mass index, waist circumference, psoas major muscle volume, and subcutaneous and visceral fat areas in relation to disease-control rate and PFS. ^[50]D5 This retrospective evidence is hypothesis-generating and does not establish body composition as a validated treatment-selection biomarker. ^[50]D5

Neoadjuvant immunotherapy and response assessment

Neoadjuvant immunochemotherapy and neoadjuvant chemoradiotherapy–immunotherapy are active areas of investigation for locally advanced ESCC. A pilot study evaluated spectral CT parameters—including 40-keV virtual monoenergetic imaging, iodine concentration, and normalized iodine concentration—in 87 patients receiving neoadjuvant immunochemotherapy, comparing responders and nonresponders and assessing independent predictors of response. ^[68]D These imaging measures may support noninvasive response evaluation, but the pilot design does not establish them as routine clinical-response or surgical-decision biomarkers. ^[68]D

A multicenter retrospective study of 51 ESCC patients treated with neoadjuvant chemoradiotherapy–immunotherapy followed by radical esophagectomy examined tumor-volume change on CT and the interval from treatment completion to surgery. ^[66]D The study evaluated associations between tumor-volume change rate, timing to surgery, and survival outcomes, but retrospective design and limited sample size constrain causal interpretation and generalizability. ^[66]D

Other investigational and targeted approaches

Earlier reviews describe investigational strategies including therapies directed at chemokine receptors, oncolytic viruses, adoptive T cells, vaccines, and combinations of immune checkpoint inhibition with radiation therapy. ^[48]D5 The supplied references do not provide contemporary randomized evidence supporting a specific molecularly targeted agent as standard therapy for esophageal cancer. Evidence for circulating tumor DNA–guided treatment monitoring comes from previously treated gastroesophageal adenocarcinoma rather than a validated ESCC-specific targeted-therapy pathway; that retrospective study examined baseline ctDNA and early ctDNA changes during trifluridine–tipiracil with or without bevacizumab. ^[12]B2b

Practical summary

For eligible patients with untreated advanced ESCC, an anti-PD-1/PD-L1 antibody plus chemotherapy is an evidence-supported first-line framework, with agent selection guided by local approvals, histology, PD-L1 methodology, comorbidity, toxicity considerations, and access. ^{[44]A1a [4]A1b} PD-L1 testing is clinically relevant but imperfect, and results should not be interpreted independently of the regimen and indication. ^[47]D5 Neoadjuvant immunotherapy-based approaches, spectral CT, tumor-volume kinetics, body-composition measures, and ctDNA monitoring remain areas requiring prospective validation before routine use as treatment-selection tools. ^{[50]D5 [68]D [66]D [12]B2b}

Scope of the evidence

Available evidence for toxicity and supportive care in esophageal cancer is predominantly retrospective and real-world, with important differences in treatment setting and regimen. The strongest directly relevant safety data come from a multi-institutional cohort of 184 patients receiving second-line nivolumab monotherapy for unresectable or metastatic esophageal cancer and a separate cohort of 71 patients receiving immune-checkpoint-inhibitor (ICI) combination therapy. ^{[10]B2b[39]C4} Earlier literature describes checkpoint inhibitors as an evolving treatment strategy in esophageal and gastric cancers but does not provide a contemporary supportive-care algorithm. ^[67]D

Immune-checkpoint-inhibitor toxicity

In the second-line nivolumab cohort, the incidence of grade 3 or higher adverse events was 14%, and no treatment-related deaths occurred. ^[10]B2b These findings support the feasibility of nivolumab monotherapy in appropriately selected patients, while emphasizing the need for routine toxicity surveillance because clinically significant toxicity still occurred in approximately one in seven patients. ^[10]B2b The study also evaluated tumor response, disease control, long-term survival, prognostic factors, and subsequent third-line treatment, indicating that toxicity assessment should be integrated with ongoing evaluation of treatment benefit and future treatment planning. ^[10]B2b

In the real-world ICI-combination cohort, the response rate among patients with measurable lesions was 58%, the disease-control rate in the full cohort was 80%, and 5 patients (7.0%) underwent successful conversion surgery. ^[39]C4 However, 13% of patients developed grade 3 or higher immune-related adverse events (irAEs), and 1 patient (1.4%) died from cholangitis. ^[39]C4 Combination therapy therefore has clinically meaningful activity but may carry more consequential immune-related or treatment-associated risk than can be inferred from response rates alone; patients should be monitored for severe toxicity and infectious or hepatobiliary complications. ^[39]C4

A separate single-center retrospective study specifically examined the relationship between irAEs and long-term survival in patients with unresectable, advanced, or recurrent esophageal cancer receiving ICI combination regimens, including ICI plus chemotherapy or ICI plus ICI. ^[18]C4 Patients were categorized according to whether irAEs occurred, and progression-free survival, overall survival, and complete or partial response rates were compared between groups. ^[18]C4 The available evidence establishes the clinical question and study design but does not provide the comparative outcome estimates in the supplied abstract; therefore, the occurrence of an irAE should not be interpreted as a validated surrogate for treatment efficacy. ^[18]C4

Baseline assessment and supportive-care considerations

Baseline metabolic status may be relevant when initiating ICI therapy. A 2026 retrospective study included 99 patients treated with ICIs, comprising 52 with renal cell carcinoma, 23 with urothelial carcinoma, and 24 with esophageal carcinoma, and evaluated baseline lipid profiles in relation to efficacy and adverse events. ^[69] The abstract reports significant associations between LDL cholesterol ≥140 mg/dL, HDL cholesterol ≤40 mg/dL, and outcomes in the renal-cell-carcinoma subgroup, but the supplied evidence does not report esophageal-cancer-specific associations or establish that lipid modification changes ICI toxicity or efficacy. ^[69] Accordingly, dyslipidemia may be documented as part of baseline clinical assessment, but the cited evidence does not justify using lipid values alone to select or withhold ICI treatment. ^[69]

Nutritional and body-composition assessment may also provide prognostic information during multimodality treatment. In 123 patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy, computed tomography at the L3 level was used to assess muscularity and adiposity, and the study evaluated myosteatosis together with systemic inflammation in relation to progression-free and overall survival. ^[51]B3b The study’s focus was prognostic rather than toxicity-directed; nevertheless, CT-derived body composition and inflammatory status may help identify patients who require closer nutritional, functional, and treatment-tolerance assessment. ^[51]B3b

Radiotherapy-related context

For early T1–2N0M0 esophageal squamous-cell carcinoma treated with definitive radiotherapy in a multicenter retrospective study of 196 patients, 78 received radiochemotherapy and 118 received radiotherapy alone. ^[52]B3b Ninety-six patients were treated with three-dimensional conformal radiotherapy and 100 with intensity-modulated radiotherapy; the median planning target-volume and gross-target-volume doses were both 60 Gy. ^[52]B3b These data describe treatment delivery and prognosis rather than specific supportive-care interventions or toxicity rates, so they should not be used to infer comparative safety between radiotherapy techniques. ^[52]B3b

Practical synthesis

Supportive care should be individualized according to regimen intensity, treatment intent, baseline comorbidity, body composition, and emerging symptoms. ^{[10]B2b[18]C4[39]C4[51]B3b[69]} Nivolumab monotherapy demonstrated a relatively low reported rate of severe adverse events and no treatment-related deaths in one real-world cohort, whereas ICI combination therapy was associated with severe irAEs and a reported fatal cholangitis event. ^{[10]B2b[39]C4} Because all cited clinical studies are retrospective, toxicity estimates may be influenced by patient selection, institutional practice, and differences in regimen composition. ^{[10]B2b[18]C4[39]C4[51]B3b[69]}

Frailty, sarcopenia, and poor performance status

Esophageal cancer commonly causes dysphagia, cachexia, and substantial loss of skeletal muscle; preoperative sarcopenia is generally assessed using the skeletal muscle index (SMI) measured on computed tomography at the third lumbar vertebra. ^[53]B2a A systematic review and meta-analysis evaluated whether low preoperative SMI was associated with short-term postoperative outcomes after esophagectomy for esophageal neoplasia, supporting incorporation of body-composition assessment into preoperative risk stratification. ^[53]B2a However, SMI thresholds and definitions varied among the included studies, so a single universal cutoff should not be assumed from this evidence alone. ^[53]B2a

Frailty is clinically relevant when selecting between trimodality treatment and definitive chemoradiotherapy. In a real-world cohort, patients receiving definitive bimodality therapy were characterized as patients who were too old, too frail, or otherwise poor candidates for surgery, or who declined surgery; the study specifically addressed populations underrepresented in clinical trials. ^[56]B3b Thus, treatment intent should be individualized according to functional status, nutritional reserve, comorbidity, operative risk, and patient preference rather than chronological age alone. ^{[53]B2a[56]B3b} Karnofsky performance status has also been associated with outcomes after radical radiotherapy, and it was an independent prognostic factor in a retrospective ESCC cohort. ^[58]D5 A randomized study of Xiaoaiping plus S-1/cisplatin enrolled patients with advanced disease who had Karnofsky performance status ≥60 and an expected survival of at least 3 months, illustrating the performance-status requirements used in some systemic-treatment studies; the supplied evidence does not establish Xiaoaiping as a standard systemic therapy. ^[17]A1b

Cervical nodal metastasis

Concurrent cervical lymph-node metastasis in thoracic esophageal cancer represents a borderline clinical situation between locoregional and distant disease, with limited Western evidence to guide treatment selection. ^[27]B2b A Dutch nationwide population-based cohort evaluated patients with resectable thoracic esophageal or gastroesophageal-junction cancer and cervical nodal metastases who received definitive chemoradiotherapy, neoadjuvant therapy followed by surgery, or chemotherapy with or without limited radiotherapy. ^[27]B2b Because this was a population-based cohort rather than a randomized comparison, treatment selection and survival differences should be interpreted as observational evidence; multidisciplinary review is appropriate when considering curative-intent local therapy versus systemic or definitive treatment. ^[27]B2b

Definitive chemoradiotherapy and radiation-dose considerations

For patients treated without surgery, definitive concurrent chemoradiotherapy remains an important strategy, particularly when operative risk is excessive or surgery is declined. ^[56]B3b In a retrospective study of stage II–III disease treated with definitive chemoradiotherapy, patients receiving <60 Gy were compared with those receiving ≥60 Gy; median doses were 50.4 Gy and 63 Gy, respectively, and most patients received concurrent 5-fluorouracil/cisplatin. ^[55]B3b These data assess the relationship between dose and locoregional control but do not by themselves establish that dose escalation is appropriate for every patient, particularly those with frailty, toxicity risk, or competing comorbidity. ^[55]B3b

Inflammatory and functional measures may provide prognostic information during radiotherapy. In a retrospective cohort of 180 patients with ESCC treated with radical radiotherapy, Karnofsky performance status, lymphatic metastasis, mid-radiotherapy systemic immune-inflammation index (SII), and the pre-/post-radiotherapy SII ratio were independent prognostic factors; median overall survival was 649 days overall, 909 days in the higher-ratio group, and 466 days in the lower-ratio group. ^[58]D5 SII should be regarded as a prognostic marker rather than a validated treatment-selection biomarker. ^[58]D5

Unresectable, recurrent, or metastatic disease

Real-world outcomes indicate that immune-checkpoint inhibitor (ICI) combinations can produce clinically meaningful responses in selected patients with unresectable or metastatic esophageal cancer. In a 71-patient multicenter cohort treated between 2021 and 2022, the response rate among patients with measurable lesions was 58%, disease control for the full cohort was 80%, 7.0% underwent conversion surgery, and grade ≥3 immune-related adverse events occurred in 13%; one patient died from cholangitis. ^[39]C4 These findings are retrospective and should not be interpreted as proof that conversion surgery is appropriate outside multidisciplinary selection. ^[39]C4

Second-line nivolumab monotherapy also demonstrated activity in a multicenter cohort of 184 patients with unresectable or metastatic disease: among 128 patients with measurable lesions, the response rate was 23%, disease control in the entire cohort was 45%, and grade ≥3 adverse events occurred in 14%, with no treatment-related deaths reported. ^[10]B2b Prognostic factors and outcomes in this study were observational and may reflect patient selection. ^[10]B2b

The occurrence of immune-related adverse events may correlate with long-term outcomes, but evidence remains limited. A single-center retrospective study evaluated patients receiving ICI combinations, including ICI plus chemotherapy or ICI plus ICI, and compared progression-free survival, overall survival, and response between patients with and without immune-related adverse events. ^[18]C4 Such associations should not be used to deliberately provoke or continue toxicity, because the study design cannot establish causality. ^[18]C4

For refractory advanced gastroesophageal cancer, nivolumab combined with irinotecan and 5-fluorouracil was investigated because both PD-1 inhibition and irinotecan-based treatment have limited activity in heavily pretreated populations; the primary objective was safety, with response, overall survival, and progression-free survival as secondary outcomes. ^[41]B2b Ramucirumab plus paclitaxel is an established second-line option in advanced gastric and gastroesophageal-junction adenocarcinoma, but a retrospective evaluation of a modified every-2-week mRAINBOW schedule was undertaken to assess efficacy and safety, and its applicability to esophageal cancer should not be extrapolated automatically. ^[57]B3b

Prior radiotherapy and malignant obstruction

Patients with malignant dysphagia or fistula after radiotherapy may require palliative endoscopic management in addition to, or instead of, further systemic therapy. In a retrospective series of 83 patients receiving a low-radial-force self-expandable metallic stent, major adverse-event rates were 6.3% in patients with prior radiotherapy and 5.9% in those without prior radiotherapy, with no significant difference reported. ^[59]D5 Stenting should therefore be individualized according to obstruction, fistula, anatomy, expected survival, and procedural risk. ^[59]D5

A retrospective study of cervical circular-stapled esophagogastrostomy reconstruction evaluated a keyhole technique intended to enlarge the anastomotic opening and reduce postoperative stricture after esophagectomy. ^[54]B3b This procedural evidence does not establish a systemic-treatment strategy but may be relevant when postoperative swallowing dysfunction complicates nutritional recovery and subsequent therapy. ^[54]B3b

Part of the Esophageal Cancer family. Cross-cutting management split across dedicated child pages:

• Esophageal Cancer , diagnostic page (definition, epidemiology, staging, biomarkers, prognosis)
• Esophageal Cancer Surgical Management , operations by stage, fertility-sparing options, sentinel node mapping, adjuvant triggers (Sedlis / Peters)
• Esophageal Cancer Radiation Management , EBRT + image-guided brachytherapy + concurrent chemoradiation, dose / fractionation, OAR constraints
• Esophageal Cancer Palliative Care , early integration, symptom management, palliative procedures, end-of-life care
• Esophageal Cancer Surveillance and Follow-up , post-treatment surveillance schedule, late toxicity, survivorship, patient counselling
• Esophageal Cancer Recurrent and Metastatic Disease , local-regional salvage, distant metastatic systemic therapy, oligometastatic disease

Pearl: Use these links to hop between management modalities; the parent Esophageal Cancer page carries diagnosis + staging that informs every decision here.